CSPC Innovation announced that CRB-701 developed by Corbus was authorized by the US FDA to launch a registered clinical trial for second-line oropharyngeal squamous cell carcinoma indications. TEMPO-1 is a randomized controlled clinical trial aimed at comparing the efficacy and safety of CRB-701 and the researchers' single-drug regimen. The main study endpoints were objective remission rate and overall survival. Corbus is expected to start patient enrollment in the third quarter of 2026.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.